AMF Tjanstepension AB Reduces Holdings in Gilead Sciences, Inc. $GILD

AMF Tjanstepension AB lessened its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 33.4% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 349,429 shares of the biopharmaceutical company’s stock after selling 175,531 shares during the period. AMF Tjanstepension AB’s holdings in Gilead Sciences were worth $38,787,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. GoalVest Advisory LLC lifted its holdings in Gilead Sciences by 7,566.7% in the 2nd quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 227 shares in the last quarter. Corundum Trust Company INC acquired a new stake in shares of Gilead Sciences in the third quarter valued at about $26,000. Harbor Asset Planning Inc. purchased a new position in shares of Gilead Sciences in the second quarter worth about $27,000. Howard Hughes Medical Institute acquired a new position in Gilead Sciences during the second quarter worth about $30,000. Finally, Putney Financial Group LLC grew its stake in Gilead Sciences by 53.4% during the 2nd quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 94 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Insider Activity at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction that occurred on Monday, December 15th. The shares were sold at an average price of $122.00, for a total value of $366,000.00. Following the completion of the transaction, the chief financial officer owned 153,503 shares of the company’s stock, valued at approximately $18,727,366. This trade represents a 1.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, October 28th. The shares were sold at an average price of $119.39, for a total transaction of $1,193,900.00. Following the completion of the transaction, the chief executive officer owned 581,203 shares of the company’s stock, valued at $69,389,826.17. This trade represents a 1.69% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 141,757 shares of company stock worth $17,569,112 over the last ninety days. Company insiders own 0.27% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently issued reports on GILD. Scotiabank initiated coverage on Gilead Sciences in a research report on Thursday, November 13th. They issued a “sector outperform” rating and a $140.00 price target for the company. Needham & Company LLC boosted their price objective on Gilead Sciences from $133.00 to $140.00 and gave the stock a “buy” rating in a research note on Thursday, November 13th. Wells Fargo & Company raised their target price on Gilead Sciences from $145.00 to $150.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 10th. Weiss Ratings reiterated a “buy (b)” rating on shares of Gilead Sciences in a report on Thursday. Finally, TD Cowen upped their price objective on shares of Gilead Sciences from $115.00 to $125.00 and gave the company a “buy” rating in a report on Thursday, October 23rd. One analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $133.52.

Gilead Sciences Stock Performance

Shares of GILD stock opened at $135.93 on Friday. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.31 and a current ratio of 1.45. The firm has a market cap of $168.65 billion, a P/E ratio of 21.07, a P/E/G ratio of 0.71 and a beta of 0.33. The firm’s 50 day moving average price is $123.98 and its 200-day moving average price is $118.68. Gilead Sciences, Inc. has a one year low of $92.26 and a one year high of $136.30.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, beating the consensus estimate of $2.16 by $0.31. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The firm had revenue of $7.77 billion during the quarter, compared to the consensus estimate of $7.42 billion. During the same quarter last year, the firm earned $2.02 EPS. The firm’s revenue for the quarter was up 3.0% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. As a group, equities research analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, December 30th. Investors of record on Monday, December 15th were paid a dividend of $0.79 per share. The ex-dividend date of this dividend was Monday, December 15th. This represents a $3.16 annualized dividend and a yield of 2.3%. Gilead Sciences’s dividend payout ratio is presently 48.99%.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.